Revised forecast
Fiscal year ending February 2027 · Full yearPrevious forecast published 9 April 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
Revenue is expected to increase because the results of 株式会社セキ薬品, which became a consolidated subsidiary in September 2026, have been included in the consolidated results. Meanwhile, merchandise sales at existing stores, particularly seasonal products, remained below expectations because of unfavorable summer weather. Accordingly, the assumptions for merchandise sales and the gross profit margin for the second half were revised, and each level of profit is expected to fall below the previous forecast even after factoring in the profit contribution from the newly consolidated subsidiary.
| Item | Details |
|---|---|
| Net Sales | 1,092,000 million yen → 1,117,900 million yen（+2.4%） |
| Operating profit | 54,000 million yen → 51,000 million yen（-5.6%） |
| Ordinary income | 55,000 million yen → 51,400 million yen（-6.5%） |
| Profit attributable to owners of the parent | 32,800 million yen → 27,400 million yen（-16.5%） |
| Net income per share | 90.62 yen and sen → 73.62 yen and sen |
| Fiscal Period Covered | Fiscal year ending February 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 9 April 2026 |
| Previous-period results | Revenue ¥1,010,336 million, EBITDA ¥68,679 million, operating profit ¥48,568 million, ordinary profit ¥50,062 million, net income attributable to owners of the parent ¥44,982 million, basic earnings per share ¥124.28 (fiscal year ended February 2026) |
| Reason for the revision | Revenue is expected to increase because the results of 株式会社セキ薬品, which became a consolidated subsidiary in September 2026, have been included in the consolidated results. Meanwhile, merchandise sales at existing stores, particularly seasonal products, remained below expectations because of unfavorable summer weather. Accordingly, the assumptions for merchandise sales and the gross profit margin for the second half were revised, and each level of profit is expected to fall below the previous forecast even after factoring in the profit contribution from the newly consolidated subsidiary. |
| Dividend forecast revision | No change (there is no revision to the dividend forecast) |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (1)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue is expected to increase because the results of 株式会社セキ薬品, which became a consolidated subsidiary in September 2026, have been incorporated. However, merchandise sales at existing stores, particularly seasonal products, fell below expectations because of unfavorable summer weather. As a result, the assumptions for merchandise sales and the gross profit margin for the second half were revised, leading to downward revisions to profit.